$0.16 EPS Expected for Summit Midstream Partners, LP (SMLP); Epizyme Has 1.46 Sentiment

February 15, 2018 - By Marguerite Chambers

Analysts expect Summit Midstream Partners, LP (NYSE:SMLP) to report $0.16 EPS on February, 22.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.16 EPS. SMLP’s profit would be $11.93 million giving it 31.88 P/E if the $0.16 EPS is correct. After having $1.22 EPS previously, Summit Midstream Partners, LP’s analysts see -86.89% EPS growth. The stock decreased 1.21% or $0.25 during the last trading session, reaching $20.4. About 69,505 shares traded. Summit Midstream Partners, LP (NYSE:SMLP) has risen 6.71% since February 15, 2017 and is uptrending. It has underperformed by 9.99% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.32 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

Foresite Capital Management Ii Llc holds 11.92% of its portfolio in Epizyme, Inc. for 1.54 million shares. Palo Alto Investors Llc owns 6.40 million shares or 5.13% of their US portfolio. Moreover, Nea Management Company Llc has 4.31% invested in the company for 6.46 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 1.19% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 369,403 shares.

The stock increased 8.88% or $1.55 during the last trading session, reaching $19. About 526,609 shares traded or 9.04% up from the average. Epizyme, Inc. (EPZM) has risen 91.85% since February 15, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on March, 8. They expect $-0.57 EPS, up 5.00% or $0.03 from last year’s $-0.6 per share. After $-0.63 actual EPS reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts -9.52% EPS growth.

Since January 1, 0001, it had 1 buying transaction, and 4 insider sales for $1.11 million activity.

Investors sentiment decreased to 0.83 in Q3 2017. Its down 0.50, from 1.33 in 2017Q2. It is negative, as 14 investors sold Summit Midstream Partners, LP shares while 16 reduced holdings. 4 funds opened positions while 21 raised stakes. 35.75 million shares or 0.01% more from 35.74 million shares in 2017Q2 were reported. Spirit Of America Corporation Ny reported 0.78% stake. Manufacturers Life Insurance The holds 2,312 shares. Neuberger Berman Gru Limited Liability Company stated it has 105,399 shares or 0% of all its holdings. Emory University accumulated 87,560 shares or 1.39% of the stock. Guggenheim Cap Ltd invested in 44,048 shares. Center Coast Advsrs Limited Partnership accumulated 1.45 million shares or 0.72% of the stock. Solaris Asset Mgmt Limited Com holds 3,225 shares. Royal Financial Bank Of Canada has 38,324 shares for 0% of their portfolio. Tph Asset Management Limited Liability owns 595,461 shares or 1.33% of their US portfolio. 34,052 are owned by Arrow Investment Advsrs Limited Com. Raymond James & Associates holds 0% or 46,950 shares. Credit Suisse Ag invested in 0% or 45,233 shares. 53,817 were accumulated by Van Eck Associate Corporation. Hmi Ltd Llc stated it has 5.15M shares. Prudential Public Limited has invested 0.01% in Summit Midstream Partners, LP (NYSE:SMLP).

Summit Midstream Partners, LP focuses on owning, developing, and operating midstream energy infrastructure assets primarily shale formations in North America. The company has market cap of $1.52 billion. The firm provides natural gas gathering, treating, and processing services. It has a 13.88 P/E ratio. It operates in five unconventional resource basins, including the Appalachian Basin, which comprises the Utica and Point Pleasant shale formations in southeastern Ohio, and the Marcellus Shale formation in northern West Virginia; the Williston Basin that consists the Bakken and Three Forks shale formations in northwestern North Dakota; the Fort Worth Basin, which includes the Barnett Shale formation in north-central Texas; the Piceance Basin that comprises the Mesaverde formation, and the Mancos and Niobrara shale formations in western Colorado and eastern Utah; and the DJ Basin, which includes the Niobrara shale formation in northeastern Colorado.

Among 9 analysts covering Summit Midstream Partners (NYSE:SMLP), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Summit Midstream Partners had 29 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by Robert W. Baird to “Outperform” on Friday, August 12. SunTrust maintained it with “Hold” rating and $24.0 target in Monday, January 29 report. Robert W. Baird maintained the stock with “Buy” rating in Friday, November 3 report. Robert W. Baird downgraded the shares of SMLP in report on Monday, August 17 to “Neutral” rating. As per Monday, September 11, the company rating was maintained by RBC Capital Markets. The rating was maintained by Goldman Sachs with “Neutral” on Thursday, May 12. The stock has “Outperform” rating by Robert W. Baird on Friday, August 11. The stock of Summit Midstream Partners, LP (NYSE:SMLP) earned “Outperform” rating by Wells Fargo on Wednesday, January 11. As per Monday, June 5, the company rating was maintained by RBC Capital Markets. The stock of Summit Midstream Partners, LP (NYSE:SMLP) has “Neutral” rating given on Friday, March 11 by Goldman Sachs.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>